ArticleThe Journal of infectious diseases2023

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.

John Fullarton et al.PubMed ↗Publisher ↗

No numbers read from the abstract.